|
MOBKL3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.84400050784461E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.26140000000774E-07 |
| Normal-vs-Stage2 |
1.95819999992963E-07 |
| Normal-vs-Stage3 |
5.03070030077879E-10 |
| Normal-vs-Stage4 |
1.77724501781995E-12 |
| Stage1-vs-Stage2 |
2.259800E-01 |
| Stage1-vs-Stage3 |
3.580000E-02 |
| Stage1-vs-Stage4 |
3.65660000000156E-05 |
| Stage2-vs-Stage3 |
7.479600E-01 |
| Stage2-vs-Stage4 |
5.262200E-02 |
| Stage3-vs-Stage4 |
5.014500E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.11639652656504E-11 |
| Normal-vs-AfricanAmerican |
3.767500E-04 |
| Normal-vs-Asian |
3.51740000004153E-06 |
| Caucasian-vs-AfricanAmerican |
6.345400E-01 |
| Caucasian-vs-Asian |
5.192200E-01 |
| AfricanAmerican-vs-Asian |
9.987600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.91789917280971E-11 |
| Normal-vs-Female |
5.43489997451019E-09 |
| Male-vs-Female |
1.135200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.52473999999181E-05 |
| Normal-vs-Age(41-60Yrs) |
7.6350037403472E-11 |
| Normal-vs-Age(61-80Yrs) |
1.89229742986186E-11 |
| Normal-vs-Age(81-100Yrs) |
2.864300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.359920E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.158300E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.545800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.881600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.905800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.349000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.037600E-02 |
| Classical-VS-Follicular |
3.551900E-02 |
| Classical-VS-Other |
1.931390E-01 |
| Classical-VS-Normal |
5.8477999997919E-08 |
| Tall-VS-Follicular |
6.195200E-01 |
| Tall-VS-Other |
7.622600E-01 |
| Tall-VS-Normal |
1.04599999994903E-07 |
| Follicular-VS-Other |
5.923000E-01 |
| Follicular-VS-Normal |
1.13289999603694E-08 |
| Other-VS-Normal |
9.965000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.94049998292201E-10 |
| Normal-vs-N1 |
2.24050000774412E-09 |
| N0-vs-N1 |
2.927600E-01 |
|
|
